NCT05261516

Interaction of Volatile Anesthetics With Magnesium

Name: Clinical Trial NCT05261516
Creator: Christoph Czarnetzki
Keywords: Neuromuscular Blockade, Magnesium Sulfate, Phase 4, drug, clinical trial, Switzerland

Interaction Between Intravenous Magnesium Sulfate and Volatile Anesthetics Compared to Propofol. A Three-center Prospective Randomized Single-blinded Electrophysiological Study

Christoph Czarnetzki·Phase 4·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Neuromuscular Blockade
Drug/Device/Intervention: Magnesium Sulfate
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Christoph Czarnetzki
Funder: University Hospital, Geneva
Location: Genève,Lugano,Sion, Switzerland

Timeline & enrollment

Phase: Phase 4
Start date: Mar 15, 2022
End date: Mar 15, 2024
Enrollment: 96 participants

Primary outcome

Change in TOF ratio after perfusion of magnesium

Summary

Magnesium and volatiles anesthetics both have an effect on the neuromuscular transmission. The primary objective of the study is to quantify the effect of a perfusion of intravenous magnesium on neuromuscular transmission measured by acceleromyography with the TofScan device in patients undergoing general anesthesia with volatile anesthetics (desflurane, sevoflurane and isoflurane) as compared to intravenous anesthesia with propofol.

ICD-10 classifications

Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05261516
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05261516 through Pure Global AI's free database. This Phase 4 trial is sponsored by Christoph Czarnetzki and is currently Not yet recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 96 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.